Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (2726)	3/23/2010 12:11:49 PM
From: Jibacoa	Respond to of 3722

Thanks Jim, That news about the change in the Treximet royalty change from 5 to 18% was mentioned when they reported the 4thQ results on March 3. finance.yahoo.com POZN has done well in the last 2 days in spite of the losses and lower revenues and is trading at the highest level since Nov 2008 <g> bigcharts.marketwatch.com On Jan28 they announced the FDA acceptance of incidence of gastric ulcer as endpoint of the current trials on Vimovo. <g> The current estimates are for it to still report a loss around $0.20 in 2010 and to report on the black around $0.07 in 2011 <g> Bernard